PODD - インスレット （Insulet Corporation）PODDのニュース
Raymond James maintains Insulet at Outperform with a price target of $350.00 2023/05/05 19:46:36 Investing.com
https://www.investing.com/news/pro/insulet-corp-receives-investment-bank-analyst-rating-update-3074807
Insulet Reports Better-Than-Expected Q1 Earnings As Omnipod 5 Launch Gains Momentum, Lifts Guidance 2023/05/05 13:16:56 Benzinga
Insulet Corporation (NASDAQ: PODD ) reported Q1 sales of $358.10 million Thursday, beating the consensus of $330.84 million . Total Omnipod revenue came in at $357.6 million, up 32.7% year-over-year. Insulet rolled out its next-generation Omnipod 5 in August 2022. Last month, the company also earned FDA clearance for the Omnipod GO, a basal-only insulin delivery device . The company reported … Full story available on Benzinga.com
BTIG maintains Insulet at Buy with a price target of $355.00 2023/05/05 11:09:37 Investing.com
https://www.investing.com/news/pro/insulet-corp-receives-investment-bank-analyst-rating-update-3074258
Insulet Corporation 2023 Q1 - Results - Earnings Call Presentation 2023/05/05 07:16:58 Seeking Alpha
The following slide deck was published by Insulet Corporation in conjunction with their 2023 Q1 earnings call.
Insulet Corporation (PODD) Q1 2023 Earnings Call Transcript 2023/05/05 01:15:19 Seeking Alpha
Insulet Corporation (NASDAQ:NASDAQ:PODD) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ETCompany ParticipantsDeborah Gordon – President-Investor RelationsJim Hollingshead – President…
$1000 Invested In Insulet 5 Years Ago Would Be Worth This Much Today 2022/08/23 14:41:04 Benzinga
Insulet (NASDAQ: PODD ) has outperformed the market over the past 5 years by 24.25% on an annualized basis producing an average annual return of 35.42%. Currently, Insulet has a market capitalization of $18.24 billion. Buying $1000 In PODD: If an … Full story available on Benzinga.com
Cowen Reiterates Outperform on Insulet on Omnipod 5 Label Expansion 2022/08/22 18:00:02 Investing.com
https://www.investing.com/news/pro/cowen-reiterates-outperform-on-insulet-on-omnipod-5-label-expansion-432SI-2877639
Insulet''s Omnipod 5 insulin pump scores FDA nod for toddlers with Type 1 diabetes 2022/08/22 13:59:57 FierceBiotech
Insulet''s Omnipod 5 insulin pump scores FDA nod for toddlers with Type 1 diabetes apark Mon, 08/22/2022 - 09:59
PODD stock on watch on FDA nod for Omnipod 5 in young children (NASDAQ:PODD) 2022/08/22 10:35:26 Seeking Alpha
Insulin pump maker Insulet Corporation (PODD) announced Monday that the FDA had greenlighted the company’s Omnipod 5 Automated Insulin Delivery System for use in children aged 2 – 5…
Insulet Announces FDA Clearance of Omnipod® 5 for Children Aged Two Years and Older with Type 1 Diabetes 2022/08/22 10:00:00 Investor Insulet
Omnipod 5 is the first tubeless AID System cleared in the U.S. for preschool children ACTON, Mass. --(BUSINESS WIRE)--Aug. 22, 2022-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today
Insulet Corporation (PODD) CEO Shacey Petrovic on Q1 2022 Results - Earnings Call Transcript 2022/05/06 21:23:07 Seeking Alpha
Insulet Corporation (NASDAQ:NASDAQ:PODD) Q1 2022 Earnings Conference Call May 05, 2022 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Shacey Petrovic -…
Insulet -11% after Wells Fargo lowers PT after Q1 earnings 2022/05/06 17:56:21 Seeking Alpha
Insulet (PODD) falls 11% after Wells Fargo analyst cuts PT to $345 from $357.The company''s Q1 earnings topped expectations and announced CEO transition.
Insulet Q1 Earnings Beats Street View, Says Omnipod 5 Rollout Is ''Progressing Very Well'' 2022/05/06 13:55:52 Benzinga
Insulet Corporation (NASDAQ: PODD ) posted Q1 profits of $27.8 million , or an EPS of $0.40, beating the consensus of $0.23. Q1 sales increased 17.1% Y/Y, or 19.3% in constant currency, to $295.4 million, exceeding the guidance range of 13% to 16% in constant currency and the consensus of $288.18 million. “We are off to a great start … Full story available on Benzinga.com